December 17, 2014 8:25 PM ET

Life Sciences Tools and Services

Company Overview of CHDI Foundation, Inc.

Company Overview

CHDI Foundation, Inc., a not-for-profit research organization, engages in discovering and developing drugs that delay or slow the progression of Huntington's disease (HD). It supports and collaborates with a network of scientists in academic and industrial laboratories in the United States and internationally to discover drugs that slow the progression or delay the onset of HD. The company also provides financial support for research, as well as organizes workshops that bring scientists together to discuss ongoing programs, explore emerging questions, evaluate new technologies, and establish new partnerships and projects. In addition, it offers research tools and information to HD researcher...

6080 Center Drive

Suite 100

Los Angeles, CA 90045

United States

Founded in 2003

Phone:

310-342-5500

Fax:

310-342-5519

Key Executives for CHDI Foundation, Inc.

President
Age: 57
Chief Operating Officer
Chief Medical Officer
Chief Administrative Officer
Chief Legal Officer
Compensation as of Fiscal Year 2014.

CHDI Foundation, Inc. Key Developments

Evotec AG and CHDI Foundation, Inc. Extends Collaboration to Find New Treatments for Huntington's Disease

Evotec AG has announced that CHDI Foundation, Inc. has extended and restated its collaboration with Evotec through 2017 to find new treatments for Huntington's disease. The collaboration-which aims to find new treatments for Huntington's disease, means that CHDI will fund up to 52 full-time scientists at Evotec over the next three years. The collaboration initially began in 2006 and has expanded considerably over this period to fully leverage Evotec's integrated neuroscience platform. The restated extension of this collaboration is a further validation of Evotec's broad drug discovery expertise in the field of neuroscience and includes an expansion to utilise Evotec's high-throughput screening and proteomics platforms. Evotec provides a full range of research activities and expertise in the neuroscience area to CHDI, including integrated biology and chemistry supported by compound and library management, target validation, stem cell research, high-content screening, computational chemistry, in vitro pharmacokinetics and protein production.

KineMed, Isis Pharmaceuticals, and CHDI Foundation Forge Huntington's Disease Therapeutic and Companion Biomarker Collaboration

KineMed, Inc., Isis Pharmaceuticals Inc. and CHDI Foundation, Inc. announced that they are collaborating to utilize KineMed's translational biomarker platform with Isis' antisense therapeutic program for Huntington's disease (HD). This collaboration, which builds on an earlier alliance between CHDI and KineMed to develop companion biomarkers of therapeutic response in HD, will provide Isis access to novel biomarkers for use in the development of an antisense drug to treat HD.

Similar Private Companies By Industry

Company Name Region
Serametrix Corporation United States
DaVinci Biomedical Research Products, Inc. United States
Dedicated Phase I, Inc. United States
XRpro Sciences, Inc. United States
Advion, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHDI Foundation, Inc., please visit www.chdi-inc.org. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.